Summary
Pfizer Inc. (PFE) filed an 8-K on October 27, 2020, to report its financial results for the third quarter of 2020. The filing primarily serves to furnish a press release announcing these results, which are incorporated by reference into the report. Investors should note that this information, while provided, is furnished and not deemed "filed" for the purposes of Section 18 of the Exchange Act, meaning it generally won't be subject to liability under that specific section unless expressly incorporated into another filing. The core of the investor information lies within the press release (Exhibit 99) which details Pfizer's performance during Q3 2020. While the 8-K itself does not contain specific financial figures, the press release would have been the source for key metrics such as revenue, earnings per share, and potentially commentary on business segment performance and outlook, especially given the context of ongoing global health events.
Key Highlights
- 1Pfizer announced its third quarter 2020 financial results via an 8-K filing on October 27, 2020.
- 2The 8-K filing incorporates by reference a press release detailing the Q3 2020 financial performance.
- 3The press release (Exhibit 99) is the primary source of detailed financial information for investors.
- 4Information furnished under Item 2.02 is not generally considered 'filed' for Section 18 liability under the Exchange Act.
- 5This filing serves as official notification and provides access to the company's latest financial report.
- 6Investors are directed to the furnished press release for specific Q3 2020 financial data and operational updates.